Hangzhou Diagens Biotechnology (HKG:2526) entered into a three-year strategic cooperation agreement with Yongjiang Laboratory, a Friday bourse filing showed.

Under the contract, the parties will jointly promote the training, optimization, validation, and demonstration application of large-scale models for medical imaging in Guangxi.

Yongjiang Laboratory is a key digital intelligence innovation platform developed by the Guangxi Zhuang Autonomous Region.